Johnson & Johnson acquires Alios BioPharma

Johnson & Johnson acquires Alios BioPharma

Johnson & Johnson acquires Alios BioPharma

Johnson & Johnson acquires private biotechnology company Alios BioPharma in cash deal for $1.75 Billion.

Alios is developing treatment for RSV – respiratory syncytial virus. Nowdays it is in Phase 2 studies.

“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, the head of research and development at Janssen Pharmaceutical Companies, a division of Johnson & Johnson. The compound Alios is developing “complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”

In January Johnson & Johnson sold it’s clinical testing division for $4.15 billion.

“We are so pleased to be joining the Janssen Pharmaceutical Companies of Johnson & Johnson, who have an impressive track record of bringing breakthrough drugs for viral diseases to market,” said Lawrence M. Blatt, chief executive of Alios. “Our portfolio of novel medications targets a diverse range of viral infections, including respiratory syncytial virus, which complements ongoing efforts by Janssen to develop innovative treatments for important and life-threatening infections.”

This year, Alios received $41 Million in Series B funding from a group of existing investors, including SR One, Novo Ventures, Novartis Ventures and the Roche Venture Fund. That’s next one after funding $32 million in Series A funding in 2009.

“Alios BioPharma’s pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation,” said Johan Van Hoof, head of infectious diseases and vaccines at Janssen. “This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide.”

Alois BioPharma advisors were  Goldman Sachs and the law firm Latham & Watkins, while the law firms Cravath, Swaine & Moore, and Baker & McKenzie advised Johnson & Johnson.

Mr. Stakebay says :

This deal helps Johnson & Johnson to expand its portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).

 

Founder, President, Director and CEO of Alios Biohparma……. Lawrence M. Blatt….(2008-present)

Chairman, Board of Directors and CEO of J & J..Alex Gorsky…(2012-present)… $16 910 960 (2014)

JOHNSON & JOHNSON

ALIOS BIOPHARMA

Revenue

$ 71.312  billion (2013)

-

Operating income

$ 15.471  billion (2013)

-

Profit

$ 13.831 billion (2013)

-

Total assets

$ 132.683 billion (2013)

-

Total Equity

$ 74.053  billion (2013)

-

Employees

128 100(2013)

-

You Might Also Like

One comment

  1. 1

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>